Table 2.
Univariate analysis of DMFS and PFS in patients with NPC (n=222)
| Variable | DMFS
|
PFS
|
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Age | 0.290 | 0.342 | ||||
| <48 years | 1.000 | 1.000 | ||||
| ≥48 years | 1.384 | 0.758–2.526 | 1.269 | 0.776–2.075 | ||
| Sex | 0.360 | 0.110 | ||||
| Male | 1.000 | 1.000 | ||||
| Female | 1.459 | 0.650–3.274 | 1.776 | 0.879–3.592 | ||
| Smoking status | 0.875 | 0.959 | ||||
| Never | 1.000 | 1.000 | ||||
| Ever | 1.046 | 0.586–1.837 | 0.988 | 0.624–1.565 | ||
| Alcohol consumption | 0.656 | 0.646 | ||||
| Never | 1.000 | 1.000 | ||||
| Ever | 0.851 | 0.413–1.754 | 1.137 | 0.661–1.957 | ||
| Histological type | 0.743 | 0.631 | ||||
| WHO I | 1.000 | 1.000 | 0.631 | |||
| WHO II | 4,416.604 | 0.000–8.29E89 | 4,441.070 | 0.000–7.438E73 | ||
| WHO III | 2,956.944 | 0.000–5.538E89 | 2,955.821 | 0.000–4.941E73 | ||
| Radiotherapy | 0.523 | 0.417 | ||||
| 2D-RT | 1.000 | 1.000 | ||||
| IMRT | 0.630 | 0.152–2.604 | 0.619 | 0.194–1.972 | ||
| Chemotherapy | 0.280 | 0.951 | ||||
| No | 1.000 | 1.000 | ||||
| Yes | 1.444 | 0.741–2.813 | 0.984 | 0.587–1.648 | ||
| T classification | 0.425 | 0.572 | ||||
| T1–2 | 1.000 | 1.000 | ||||
| T3–4 | 1.011 | 0.984–1.040 | 1.007 | 0.984–1.030 | ||
| N classification | 0.018 | 0.007 | ||||
| N0–1 | 1.000 | 1.000 | ||||
| N2–3 | 1.034 | 1.006–1.064 | 1.032 | 1.009–1.057 | ||
| Clinical stage | 0.028 | 0.046 | ||||
| I–II | 1.000 | 1.000 | ||||
| III–IV | 1.037 | 1.004–1.071 | 1.026 | 1.000–1.052 | ||
| CXCR4 rs2228014 | 0.998 | 0.833 | ||||
| TT | 1.000 | 1.000 | ||||
| CT | 0.955 | 0.229–3.980 | 1.507 | 0.367–6.194 | ||
| CC | 0.958 | 0.214–4.285 | 1.403 | 0.324–6.075 | ||
| CXCL12 rs1801157 | 0.044 | 0.062 | ||||
| AA | 1.000 | 1.000 | ||||
| GA | 0.384 | 0.171–0.864 | 0.425 | 0.208–0.871 | ||
| GG | 0.370 | 0.158–0.866 | 0.486 | 0.234–1.008 | ||
| 0.013 | 0.021 | |||||
| GA + GG | 0.378 | 0.176–0.811 | 0.451 | 0.230–0.885 | ||
Note: P<0.05 was considered statistically significant.
Abbreviations: DMFS, distant metastasis-free survival; PFS, progression-free survival; NPC, nasopharyngeal carcinoma; HR, hazard ratio; CI, confidence interval; WHO, World Health Organization; 2D-RT, two-dimensional radiotherapy; IMRT, intensity-modulated radiotherapy; T, tumor; N, node; CXCL12, chemokine ligand 12; CXCR4, chemokine receptor 4.